 |
|
Therapy of Pemphigus Vulgaris
Arch Dermatol. 1999;135:76-78.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
HOW SHOULD a patient with pemphigus vulgaris (PV) be treated? Unfortunately, there is no easy answer to this question for several reasons. First, there is not one therapy that is clearly indicated and effective in all patients. Thus, therapy has to be tailored for each patient. Second, as was previously well documented by Bystryn and Steinman,1 there are few, if any, controlled studies for most therapies used for PV. Because of this dearth of studies, opinions regarding the therapy of pemphigus are based on reports of groups of patients without concomitant controls interpreted in light of individual clinical experience. In that sense, this editorial reflects my individual interpretation of the literature in light of my experience in treating patients with pemphigus.
Before the advent of corticosteroid therapy around 1950, PV was almost uniformly fatal within 5 years. In his classic 1965 monograph, Pemphigus and Pemphigoid, Lever2 summarizes the prognosis . . . [Full Text of this Article]
RELATED ARTICLE
Mycophenolate Is Effective in the Treatment of Pemphigus Vulgaris
Alexander H. Enk and Jürgen Knop
Arch Dermatol. 1999;135(1):54-56.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Kaposi's Sarcoma Resolves After Sirolimus Therapy in a Patient With Pemphigus Vulgaris
Saggar et al.
Arch Dermatol 2008;144:654-657.
ABSTRACT
| FULL TEXT
A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus.
Beissert et al.
Arch Dermatol 2006;142:1447-1454.
ABSTRACT
| FULL TEXT
Pemphigus--Diseases of Antidesmosomal Autoimmunity
Udey and Stanley
JAMA 1999;282:572-576.
FULL TEXT
The Role of Mycophenolate Mofetil in the Management of Pemphigus
Nousari et al.
Arch Dermatol 1999;135:853-854.
FULL TEXT
|
